Moomoo AI 已提取核心信息
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.
2024年1月19日，Altamira Therapeutics Ltd.宣布与H.C. Wainwright & Co., LLC启动市场发行协议，以发行和出售总价值不超过166万美元的普通股。销售将在 “在市场上” 的基础上进行，这意味着它们将通过纳斯达克资本市场或其他交易平台以现行市场价格出售。H.C. Wainwright & Co. 将获得按所售股票总销售价格3.0％的佣金。此次发行不受最低销售要求的约束，出售给Altamira Therapeutics的股票总数和净收益尚无法确定。一旦总销售额达到166万美元或任何一方终止协议，此次发行将结束。在此之前，该公司于2023年12月终止了先前与A.G.P./Alliance Global Partners的市场发行计划，该计划出售了价值约1,306万美元的普通股。
2024年1月19日，Altamira Therapeutics Ltd.宣布与H.C. Wainwright & Co., LLC启动市场发行协议，以发行和出售总价值不超过166万美元的普通股。销售将在 “在市场上” 的基础上进行，这意味着它们将通过纳斯达克资本市场或其他交易平台以现行市场价格出售。H.C. Wainwright & Co. 将获得按所售股票总销售价格3.0％的佣金。此次发行不受最低销售要求的约束，出售给Altamira Therapeutics的股票总数和净收益尚无法确定。一旦总销售额达到166万美元或任何一方终止协议，此次发行将结束。在此之前，该公司于2023年12月终止了先前与A.G.P./Alliance Global Partners的市场发行计划，该计划出售了价值约1,306万美元的普通股。
有用
没用